Pfizer wants the oncology drug business being developed (and very well) by Seagen. Among other products, Seagen has the lymphoma ...Read more
INVESTOR TIMES is an independent publication of economic, finance and investment content. Our expert analysis and carefully curated news empower you to make informed decisions in the complex world of finance. Stay ahead of the curve with our timely articles and gain valuable insights from industry experts.
Any information contained in INVESTOR TIMES is for educational and/or informational purposes only, it is not financial and/or investment advice. The site owner and author are not liable for any actions taken based on the information provided. INVESTOR TIMES may obtain economic retribution by recommending services or products of third parties. INVESTOR TIMES does not accept, nor will it accept in the future, subsidies or funds from Governments, political parties or public institutions.